| AURINIA PHARMACEUT. |
| Kanada |
| Gesundheit |
| CA05156V1022 / A1W7D4 |
| IKAP (Frankfurt) / AUPH (NASDAQ) |
| FRA:IKAP, ETR:IKAP, IKAP:GR, NASDAQ:AUPH |
| - |
| https://www.auriniapharma.. |
|
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical need. Aurinia Pharmaceuticals develops and commercializes LUPKYNIS, an oral treatment for adults with active lupus nephri..
>Volltext.. |
| 2074.48 Mio. EUR |
| 1742.03 Mio. EUR |
| 279.77 Mio. EUR |
| 143.72 Mio. EUR |
| 282.12 Mio. EUR |
| 2.14 EUR |
| 57.6 Mio. EUR |
| 161.51 Mio. EUR |
| 156.57 Mio. EUR |
| 4.44 |
| 23.53% |
| 434.33% |
| - |
| - |
| - |
| - |
| AURINIA |
| 30.10.26 |
|
||||
|
||||
|